Actos and Bladder Cancer: A recent study about several reports investigating actos and bladder cancer concluded that a clinically significant increased risk of bladder cancer occurs during prolonged actos use.
Actos and bladder cancer lawsuits are on the rise and an MDL was setup in the U.S. District Court for the Western District of Louisiana. The published study goal was to determine whether thiazolidinedione use is associated with a risk of bladder cancer.
The study searched many mainstream databanks (using 18 studies) and conducted meta-analysis on the overall risks of bladder cancer with pioglitazone or rosiglitazone. The analysis concluded that a significantly higher overall risk of bladder cancer with pioglitazone (ACTOS).
Actos is sold under the brand-name Actos ((pioglitazone) class of drugs which help to lower blood glucosue levels), may be sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact) and may be used along with diet and exercise to improve control of blood sugar in adults with type 2 diabetes mellitus.
Actos (pioglitazone) was first approved for use in the United States in 1999. In 2003, the U.S. Food and Drug Administration (FDA) requested that the manufacturer of Actos, Takeda Pharmaceuticals, conduct a ten-year study to evaluate whether Actos is associated with an increased risk of bladder cancer.
We are currently investigating claims involving the development of bladder cancer arising from the use of Actos and can help you file an actos lawsuit.
For more information on actos and bladder cancer, click here.
At the Gooch Law Firm, we pride ourselves on providing our clients reliable representation for even the most challenging cases. If you or a loved one have taken Actos and are now suffering from side effects related to Actos (e.g., bladder cancer) and would like your case evaluated, contact our office at 1.844.329.5955.
WE ARE HERE TO HELP YOU PROTECT YOUR LEGAL RIGHTS